STX-478-101

BMS CA244-0001

MK-3120-002-00

DS2243-054

REGN7075

F60089IV101

IMA402-101

PANTUMOR 1479-0009

222730

ANV600-001

IMC-R117C-1004

SGNCEA5C-001

STX-241 FIH (F60087CI101)

RMC-LUNG-101A

RMC-LUNG-101

STX-721-101

D6900C00001

M22TGA

IMC-F106C-101 (PRAME)

TCD17620

MCLA-129-CL01

GO43860

XL092-001

INCB 123667-101

PROACTIVE

CyPep-1

VHIO17002

Phase 1, Open-Label, Multicenter, First-In-Human Trial of Ds-2243a in Participants With Advanced Solid Tumors



<ul id="block-d38ee240-c089-4835-bdcf-3446321f2285" class="wp-block-list">
<li>Code NKI: M24FDS</li>



<li>Code firma: DS2243-054</li>



<li>Code clinicaltrials.gov: NCT06644755</li>
</ul>



Principal Investigator



Prof. Dr. N. Steeghs



Drugs



DS-2243a HLA-A2/NY-ESO x CD3 bispecific T-cell engager



<h2 class="wp-block-heading" id="block-c1c51c19-a1d4-4fcf-ae65-6e843e422af8">Summary</h2>



This 2-part study will evaluate safety, tolerability, and clinical efficacy of DS-2243a as a treatment for participants with advanced solid tumors.



Read more on <a href="https://clinicaltrials.gov/study/NCT06644755">clinicaltrials.gov</a>.



<h2 class="wp-block-heading">Additional comments</h2>



<ul class="wp-block-list">
<li>Synovia sarcoma &#8211; open</li>



<li>Myxoid/round cell liposarcoma &#8211; open</li>



<li>NSCLC &#8211; closed</li>



<li>Urothelial carcinoma &#8211;closed</li>
</ul>